Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 5/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249348 | 0.86 | LCAT (0.36) | LCATMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20249429 | 0.84 | LCAT (0.33) | LCATMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20249446 | 0.84 | LCAT (0.33) | LCATMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20249444 | 0.84 | LCAT (0.33) | LCATMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL18291190 | 0.83 | EGFR (0.37) | EGFRMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20255518 | 0.80 | LMNA (0.34) | EGFRMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20255139 | 0.79 | HRH4 (0.31) | HRH4 | |
| SCHEMBL20249147 | 0.79 | LMNA (0.40) | LCATMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL20249356 | 0.76 | TRPV1 (0.42) | LCATTRPV1HRH4 | |
| SCHEMBL20249359 | 0.76 | TRPV1 (0.42) | LCATTRPV1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | LCAT 4156/4885EGFR 567/4885MEN1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.